Chronic disease management in the post COVID era - the value of point of care testing for cardiovascular risk and kidney disease management in diabete...
Kunihiro Matsushita, Josef Coresh, Yingying Sang, John Chalmers, Caroline Fox, Eliseo Guallar, Tazeen Jafar, Simerjot K Jassal, Gijs W D Landman, Paul Muntner, Paul Roderick, Toshimi Sairenchi, Ben Schöttker, Anoop Shankar, Michael Shlipak, Marcello Tonelli, Jonathan Townend, Arjan van Zuilen, Kazumasa Yamagishi, Kentaro Yamashita, Ron Gansevoort, Mark Sarnak, David G Warnock, Mark Woodward, Johan Ärnlöv, CKD Prognosis Consortium
Estimated glomerular filtration rate and albumin-to-creatinine ratio testing for cardiovascular risk assessment
Johan Sundström, Johan Bodegard, Andreas Bollmann, Marc G Vervloet, Patrick B Mark, Avraham Karasik, Tiago Taveira-Gomes, Manuel Botana, Kåre I Birkeland, Marcus Thuresson, Levy Jäger, Manish M Sood, Gijs VanPottelbergh, Navdeep Tangri; on behalf of the CaReMe CKD Investigators
Prevalence, outcomes and cost of chronic kidney disease
Alessandro Gasparini, Marie Evans, Josef Coresh, Morgan E Grams, Olof Norin, Abdul R Qureshi, Björn Runesson, Peter Barany, Johan Ärnlöv, Tomas Jernberg, Björn Wettermark, Carl G Elinder, Juan-Jesüs Carrero
Albuminuria testing in diabetic patients and chronic kidney disease
Chronic kidney disease is a common and often silent condition – up to one in ten adults could be affected in Europe, Canada and Israel, yet only one-third of these will have had a diagnosis1.
Should you screen for kidney damage? What do the guidelines say?
Chronic kidney disease is a common and often silent condition – up to one in ten adults could be affected in Europe, Canada and Israel, yet only one-third of these will have had a diagnosis1.
Chronic kidney disease is a common and often silent condition – up to one in ten adults could be affected in Europe, Canada and Israel, yet only one-third of these will have had a diagnosis1.
Impact of ACR POC testing on the diagnosis and management of diabetic kidney disease
